25 May 2022

Dr Sonya Miller Featured in PharmaVoice

Sonya Miller follows the science. In 2017, she followed it so completely and with such focus into a crowded conference room that she accidentally sat next to the CEO of TauRx Pharmaceuticals and talked herself into a job.

Our Head of Medical Affairs and Medical Oversight Lead, Dr Sonya Miller, recently spoke with PharmaVoice to discuss her route into TauRx, the importance of optimism in the industry, and the impact tau science is having on Alzheimer’s disease research.

“It’s one of the last great frontiers in medicine - you can’t help but want to keep that optimism to enhance understanding and increase the ability to do something about it.”

Read the article here

Learn More

More news

MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Doctor examining MRI, MRT, CT scan image of human brain. Medical treatment concept. Diagnosis of the disease humans head. Close up.

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

Further reading

For decades, Professor Claude Wischik, co-founder and CEO of TauRx, has led a scientific research team dedicated to finding an effective treatment for neurodegenerative diseases.

Doctor or nurse caregiver with senior couple at home or nursing home

Clinical trials

TauRx recently completed its latest Phase III clinical trials in Alzheimer’s disease and in the rare neurodegenerative disorder, behavioural variant frontotemporal dementia (bvFTD).

Gears. Cog mechanism, engine system, operation progress, gear shift, industry innovation, engineering solution, technology concept.

Environmental, Social and Governance at TauRx

Maintaining integrity, accountability and transparency in our pursuit of life-changing treatments